Skip to main content
DrugPrice

Specialty Drug

A high-cost medication, typically above $1,000 per month, that treats complex or chronic conditions and often requires special handling, storage, or administration.

How It Works

Specialty drugs represent roughly 2% of prescription volume but 51% of total U.S. drug spending according to IQVIA's 2024 National Sales Perspectives report. They include biologics (Humira, Stelara, Dupixent), oncology agents (Keytruda at ~$200,000/year, Opdivo, Revlimid), gene and cell therapies (Zolgensma at $2.1M, Casgevy at $2.2M, Hemgenix at $3.5M), and complex small molecules (Sovaldi, originally $84,000 per 12-week hepatitis C course). Definitions vary: CMS defines specialty for Medicare Part D as drugs with a negotiated price above $830/month in 2024, while commercial payers often use $1,000/month thresholds. Specialty drugs typically require specialty pharmacy dispensing (Accredo, CVS Specialty, AllianceRx Walgreens Prime), prior authorization, REMS compliance where applicable, and often cold-chain logistics. Part D plans place specialty drugs on Tier 5 with 25-33% coinsurance, which historically created catastrophic out-of-pocket exposure. The IRA's 2025 Part D redesign (which caps annual out-of-pocket spending at $2,000) dramatically changes the patient economics: a Keytruda patient who previously faced $13,000-plus in annual OOP costs now caps at $2,000. Specialty drug spending growth has been the single biggest driver of commercial pharmacy benefit cost increases over the past decade, averaging 10-15% annual growth against roughly 2% for traditional pharmacy.

Related Terms

  • Biologic Drug, A complex medication derived from living cells, including monoclonal antibodies, vaccines, and cell therapies, that treats serious conditions like cancer and autoimmune diseases.
  • Formulary, A list of prescription drugs covered by an insurance plan, organized into tiers that determine how much the patient pays for each drug.
  • Prior Authorization, A requirement by an insurer that a patient's doctor must get approval before the plan will cover a specific drug, used to control costs and ensure appropriate use.
  • Medicare Part D Redesign (2025), The IRA-mandated restructuring of Medicare Part D, effective January 1, 2025, that caps annual out-of-pocket drug spending at $2,000 and shifts cost-sharing liability among plans, manufacturers, and government.

Explore Drug Data

Most Expensive DrugsGeneric Drug WatchSearch All Drugs

About This Definition

This definition is part of the DrugPrice Drug Pricing Glossary, 49 terms explaining how prescription drug pricing works in the United States. All definitions are written in plain language for patients, caregivers, journalists, and healthcare professionals.

this entity is one of the U.S. Medicare prescription-drug pricing concepts that recurs across this site. The definition above is the technical answer; the paragraphs below add the practical context for how the concept connects to the CMS Medicare Part D Drug Spending data data behind every per-entity page on the site.

In the CMS Medicare Part D Drug Spending data data, this concept shapes one or more of the fields that drive the per-entity grades and rankings on this site. The methodology page describes which fields feed into which output; this glossary entry documents the underlying term.

Source: CMS Medicare Part D Spending, 2026.